Unicancer GI PRODIGE 24/CCTG PA.6 trial’,  is a multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas.

Dr. Alice Wei, Associate Professor of Surgery & Institute of Health Policy, Management and Evaluation at the University of Toronto, is the Canadian Co-chair for the trial and the Pancreas Research group at UHN’s Princess Margaret Cancer Centre accrued many of the Canadians for this cooperative group study between Unicancer and the Canadian Cancer Trials Group.

Presented at the ASCO meeting in Chicago this summer, the study concluded that adjuvant mFOLFIRINOX is safe and significantly improves DFS, MFS and OS compared to gem.

The abstract is available at the following link: https://meetinglibrary.asco.org/record/159164/abstract;